Brief: Epiprotect® Demonstrates Significantly Lower Infection Risk In Major Pediatric Study

S2Medical AB (publ)

20/06/2024 11:31

June 20 (Reuters) - S2Medical AB (publ)  S2ME.ST :
    * EPIPROTECT® DEMONSTRATES SIGNIFICANTLY LOWER INFECTION
RISK IN
MAJOR PEDIATRIC STUDY
    * EXPECTS THAT RESULTS WILL ACCELERATE COMMERCIALIZATION OF
EPIPROTECT PRODUCTS

Source text for Eikon:  ID:nWkr18M8ds 
Further company coverage:  S2ME.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))